NYSE
$154.14▲ 2.01%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $294.11BShares out 19.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 9.8Pre-market26.09.08 19:056-KKey event#●●●#●●●#●●●
NOVARTIS AGBullish
Novartis announced that the Phase III HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1) failed to meet its primary endpoint of vHOT. The company is evaluating the full dataset to determine the next development steps while maintaining its 2025-2030 sales CAGR guidance of 5-6%.…more
$154.14+2.01%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.4After-hours26.09.05 06:226-KKey event
NOVARTIS AG
Novartis announced that its Phase III Lp(a)HORIZON trial for pelacarsen failed to meet its primary endpoint of reducing the risk of major adverse cardiovascular events (MACE) in patients with elevated Lp(a) and established cardiovascular disease. While the study of 8,323 participants showed that pelacarsen successfully lowered Lp(a) levels, it did not demonstrate a reduction in cardiovascular death, non-fatal myocardial infarction, or stroke compared to placebo.…more
$154.14+2.01%vs prev closeView filingShare - 9.1Pre-market26.09.01 19:216-KKey event
NOVARTIS AG
Novartis announced that its Phase III REMODEL-1/-2 trials for remibrutinib in relapsing multiple sclerosis (RMS) met the primary endpoint by significantly reducing the annualized relapse rate (ARR) compared to teriflunomide. The drug also demonstrated a clinically meaningful delay in disability progression and a favorable safety profile, leading Novartis to plan global regulatory submissions.…more
$154.14+2.01%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoRegular26.10.24 01:44Bullish#●●●#●●●#●●●
Novartis Reports Positive Phase III Results for Remibrutinib in Multiple Sclerosis…more
Novartis announced that its drug candidate remibrutinib significantly reduced the annualized relapse rate in Phase III trials for relapsing multiple sclerosis. These results demonstrate the drug's efficacy and safety, supporting its potential for future regulatory approval.…more
$154.14+2.01%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 2d agoPre-market26.10.23 20:53
●●●●●●●● ●●●●● ●●●●●●
Novartis announced that its Phase III NATALEE study showed Kisqali reduces the risk of death by approximately 20% in patients with stage II and III HR+/HER2- early breast cancer. This clinical data strengthens the drug's position as a key treatment option for high-risk recurrence patients.…more
$154.14+2.01%vs prev closeShareBenzinga - 5d agoRegular26.10.20 00:13
●●●●●●●● ●●●●● ●●●●●●
Novartis' rapcabtagene autoleucel has been granted Orphan Drug Designation by the FDA for the treatment of idiopathic inflammatory myopathies. This status provides the company with development incentives and regulatory support for the therapy.…more
$154.14+2.01%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report